Submitted by endpointsnews6292 in business
Omeros said Monday that its treatment candidate for a certain kidney disease failed a Phase III study, and investors shaved nearly half the share price $OMER in reaction to the news. The late-stage flop in immunoglobulin A nephropathy, or IgAN, is a blow to O…